MedTrace Logo

Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes

NCT00609856 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2008-02-07

No results posted yet for this study

Summary

Pioglitazone and insulin glargine are equally effective in achieving glycemic control in secondary drug failure of type 2 diabetes but the mechanisms of actions are different.

Conditions

Interventions

DRUG

pioglitazone

tablet, 30 mg, once daily, 26 weeks

DRUG

insulin glargine

subcutaneous injection, start dose 6-10 units, once daily, 26 weeks

Sponsors & Collaborators

  • Medical Research Council

    collaborator OTHER_GOV

  • Skane County Council Research & Development Foundation

    collaborator UNKNOWN

  • Skane University Hospital

    lead OTHER

Principal Investigators

  • Leif Groop, Professor · Department of Clinical Sciences, Division of Diabetes & Endocrinology, Lund University, Malmö University Hospital, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00609856 on ClinicalTrials.gov